Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thrombopoietin after immunosuppressive therapy for severe aplastic anemia
ChiCTR-OCH-13003801Phase 4Completed
- Sponsor
- Tianjin Medical University General Hospital
- Start
- Nov 2013
- Modality
- Hormones & Growth Factors → Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of thrombopoietin in aplastic anemia (2 arms), sponsored by Tianjin Medical University General Hospital. Primary endpoints: Recovery of megakaryocytes in the bone marrow, Recovery of erythropoiesis in the bone marrow and 5 more. Started Nov 2013; status: completed.
02
Drugs
thrombopoietin
03
Conditions
aplastic anemia
Beyond the preview
Go deeper on ChiCTR-OCH-13003801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OCH-13003801.